Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network

Table 1

Demographic and clinical features of patients enrolled.

Demographic and clinical information
Age at disease onset in years, mean (SD)
Age at diagnosis in years, mean (SD)
Age at enrollment in years, mean (SD)
Male/female patients	10/14
Patients with pediatric onset-TRAPS, (%)	13 (54.2)
Patients with adult onset-TRAPS, (%)	11 (45.8)
High-/low-penetrance mutations	6/18
Family members with symptoms, (%)	10 (41.7)
Relapsing-remitting disease course, (%)	18 (75)
Chronic disease course, (%)	6 (25)
Duration of flares	10.8 ± 7.9
Flares/year	2.43 ± 0.8
Amyloidosis at diagnosis	1 (4.2)
Clinical manifestations during flares, (%)
Thoracic pain	10 (41.7)
Pericarditis	9 (37.5)
Pleuritis	2 (8.3)
Abdominal pain	13 (54.2)
Pharyngitis	9 (37.5)
Oral aphthosis	6 (25)
Skin rash	9 (37.5)
Lymphadenopathy	8 (33.3)
Myalgia	15 (62.5)
Arthralgia	17 (70.8)
Arthritis	5 (20.8)
Periorbital pain	4 (16.7)
Laboratory findings
Median erythrocyte sedimentation rate, mm/1 h (IQR)	55.7 (42)
Median C-reactive protein, mg/L (IQR)	7.7 (10.5)
Median serum amyloid A, mg/L (IQR)	59.7 (63)
Proteinuria, (%)	1 (4.2)

Abbreviations: IQR: interquartile range; : number of patients; SD: standard deviation; TRAPS: tumor necrosis factor associated periodic syndrome.